Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 7/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930959 | 0.88 | HCAR3 (0.42) | LPAR1LPAR2AURKARPS6KB1PRKCI | |
| SCHEMBL9930301 | 0.83 | AURKA (0.35) | AURKARPS6KB1BRAFERN1MAPT | |
| SCHEMBL9930605 | 0.82 | SIRT2 (0.45) | LPAR1LPAR2AURKARPS6KB1BRAF | |
| SCHEMBL9930627 | 0.82 | EIF4EBP1 (0.35) | LPAR1LPAR2AURKARPS6KB1EIF4EBP1 | |
| SCHEMBL9930617 | 0.81 | CSNK2A1 (0.39) | AURKAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL9930221 | 0.80 | HCAR3 (0.40) | LPAR2BRAFPRKCIALDH1A1MAPT | |
| SCHEMBL9930438 | 0.79 | JAK2 (0.42) | LPAR1LPAR2BRAFPRKCIALDH1A1 | |
| SCHEMBL9930988 | 0.78 | AURKA (0.43) | AURKARPS6KB1BRAFERN1MAPT | |
| SCHEMBL9930841 | 0.77 | YTHDC1 (0.35) | LPAR1LPAR2BRAFALDH1A1MAPT | |
| SCHEMBL15541357 | 0.77 | CSNK2A1 (0.43) | PRKCIALDH1A1MAPTMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | LPAR1 3291/4885LPAR2 3517/4885AURKA 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.